TRPC6 (Transient Receptor Potential Cation Channel Subfamily C Member 6) encodes a non-selective calcium-permeable cation channel belonging to the TRPC (Transient Receptor Potential Canonical) family. TRPC6 is activated by diacylglycerol (DAG), mechanical stretch, and various receptor-mediated signaling pathways. [1] The channel is widely expressed in numerous tissues, including the brain, kidney, heart, and lung, where it participates in diverse physiological processes ranging from neuronal signaling to vascular tone regulation. [2]
The TRPC6 gene is located on chromosome 11q22.1 and consists of 13 exons encoding a protein of approximately 931 amino acids. The channel protein features six transmembrane domains (S1-S6), with the pore-forming region located between S5 and S6. Like other TRPC channels, TRPC6 forms tetramers that can function as homomers or heteromers with other TRPC subunits (particularly TRPC3 and TRPC7). [1:1] The N-terminal domain contains multiple ankyrin repeat domains that are thought to be involved in protein-protein interactions and channel regulation.
Within the central nervous system, TRPC6 is expressed in various brain regions including the cerebral cortex, hippocampus, basal ganglia, and cerebellum. [3] In neurons, TRPC6 is primarily localized to the plasma membrane of soma and dendrites, where it contributes to synaptic plasticity, dendritic spine morphology, and excitability regulation. [4] Astrocytes and microglial cells also express TRPC6, suggesting roles in neuroimmune signaling and glial function. [5]
Emerging evidence links TRPC6 to Alzheimer's disease (AD) pathogenesis. TRPC6-mediated calcium influx regulates amyloid precursor protein (APP) processing and amyloid-beta (Aβ) production through mechanisms involving calpain activation and secretase activity. [6] Studies have shown that TRPC6 overexpression reduces Aβ-induced neuronal toxicity, while TRPC6 deficiency exacerbates cognitive deficits in mouse models of AD. [7] Additionally, TRPC6 contributes to tau phosphorylation through calcium-dependent kinase pathways, potentially linking Aβ and tau pathologies. [8]
In Parkinson's disease (PD), TRPC6 appears to play both protective and pathogenic roles depending on cellular context. TRPC6 channels protect dopaminergic neurons from mitochondrial toxins such as 6-hydroxydopamine (6-OHDA) and MPTP through activation of survival pathways including PI3K/Akt and ERK1/2. [9] However, dysregulated TRPC6 activity may contribute to calcium dyshomeostasis in PD, a hallmark of dopaminergic neuron vulnerability. [10] Alpha-synuclein aggregation, a key pathological feature of PD, has been shown to modulate TRPC6 channel function, potentially creating a feed-forward loop of calcium dysregulation. [11]
TRPC6 dysfunction has been implicated in amyotrophic lateral sclerosis (ALS). Motor neurons are particularly vulnerable to calcium dysregulation due to their high metabolic demands and limited calcium buffering capacity. TRPC6 channels contribute to calcium homeostasis in motor neurons, and their dysregulation may accelerate disease progression. [12] Studies in ALS mouse models have identified altered TRPC6 expression in spinal cord motor neurons, suggesting a potential therapeutic target. [13]
TRPC6 has been studied in several additional neurodegenerative and neurological conditions:
TRPC6 is activated through multiple signaling mechanisms:
Downstream signaling pathways include:
TRPC6 represents a potential therapeutic target for neurodegenerative diseases:
Key proteins that interact with TRPC6 include:
Study of TRPC6 in neurodegeneration employs:
TRPC6 is a calcium-permeable cation channel with diverse roles in neuronal function and neurodegenerative disease pathogenesis. While initially characterized in kidney and cardiovascular systems, growing evidence supports important functions in the brain across multiple neurodegenerative conditions including Alzheimer's disease, Parkinson's disease, and ALS. The channel's involvement in calcium homeostasis, synaptic plasticity, and cell survival signaling makes it an attractive therapeutic target. However, the complex regulation of TRPC6 and its cell-type-specific functions require careful consideration for drug development. Further research is needed to fully elucidate TRPC6's role in neurodegeneration and translate these findings into clinical applications.
TRPC6: Function and Physiology. 2020. ↩︎ ↩︎ ↩︎
TRPC6 in Synaptic Plasticity. 2020. ↩︎
Calcium Dyshomeostasis in PD. 2018. ↩︎
TRPC6 in Motor Neuron Disease. 2021. ↩︎
TRPC6 in Epilepsy. 2020. ↩︎
TRPC6 Antagonists in Disease. 2020. ↩︎